Literature DB >> 12015273

Confirmation of cocaine exposure by gas chromatography-mass spectrometry of urine extracts after methylation of benzoylecgonine.

Maurício Yonamine1, Ovandir Alves Silva.   

Abstract

Volatility and thermal stability are necessary physical-chemical properties for analysing a substance by gas chromatography. A derivatization step is required before gas chromatography of benzoylecgonine (the main metabolite of cocaine). In the literature, reactions such as silylation, perfluoroalkylation or alkylation are the most frequently used to derivatize benzoylecgonine. However, they allow the formation of products sensitive to moisture or require a purification step. So, a procedure to derivatize benzoylecgonine with diazomethane before gas chromatographic analysis was evaluated. A study was performed to evaluate the efficiency of conversion of benzoylecgonine in cocaine, the necessary time for reaction and the stability of ethereal solution of diazomethane. The reaction was shown to be very fast in mild conditions and there was no need for a further purification step. When benzoylecgonine was extracted from urine by solid-phase extraction and derivatized with diazomethane, concentrations as low as 25 ng/ml could be detected using GC-MS in the full scan mode.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12015273     DOI: 10.1016/s0378-4347(01)00516-3

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Validation of LC-TOF-MS screening for drugs, metabolites, and collateral compounds in forensic toxicology specimens.

Authors:  Fessessework Guale; Shahriar Shahreza; Jeffrey P Walterscheid; Hsin-Hung Chen; Crystal Arndt; Anna T Kelly; Ashraf Mozayani
Journal:  J Anal Toxicol       Date:  2012-11-01       Impact factor: 3.367

2.  Bedside point of care toxicology screens in the ED: Utility and pitfalls.

Authors:  Ashish Bhalla
Journal:  Int J Crit Illn Inj Sci       Date:  2014-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.